INT120827

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 2004
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.24
Pain Relevance 2.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CX3CL1) extracellular region (CX3CL1) plasma membrane (CX3CL1)
cytoplasm (CX3CL1)
CX3CL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Morphine 12 99.84 Very High Very High Very High
analgesia 6 99.48 Very High Very High Very High
allodynia 4 97.84 Very High Very High Very High
Pain 6 97.60 Very High Very High Very High
Hyperalgesia 4 97.24 Very High Very High Very High
tolerance 7 96.68 Very High Very High Very High
opiate 1 95.92 Very High Very High Very High
cytokine 9 93.00 High High
Inflammation 42 92.64 High High
Spinal cord 2 88.32 High High
Disease Link Frequency Relevance Heat
Hyperlipidemia 21 99.82 Very High Very High Very High
Neuropathic Pain 5 97.84 Very High Very High Very High
Pain 3 97.60 Very High Very High Very High
Hyperalgesia 5 97.24 Very High Very High Very High
Diabetes Mellitus 25 93.88 High High
INFLAMMATION 40 92.64 High High
Coronary Artery Disease 45 90.40 High High
Diabetes Mellitus-type I 24 78.88 Quite High
Atherosclerosis 18 77.68 Quite High
Cv General 3 Under Development 1 71.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Taken together, these results suggest that IL-1 and fractalkine are endogenous regulators of morphine analgesia and are involved in the increases in pain sensitivity that occur after chronic opiates.
Regulation (regulators) of fractalkine associated with pain, opiate, analgesia and morphine
1) Confidence 0.14 Published 2004 Journal J. Neurosci. Section Abstract Doc Link 15317861 Disease Relevance 0.89 Pain Relevance 2.74
These data indicate that the fractalkine levels were similar to control values and that acute hyperlipemia did not alter fractalkine levels in patients, whereas it did so in controls.
Neg (not) Regulation (alter) of fractalkine associated with hyperlipidemia
2) Confidence 0.12 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2762434 Disease Relevance 1.29 Pain Relevance 0.19
However, to date, no therapeutics targeting fractalkine or CX3CR1 are in clinical use.


Neg (no) Regulation (targeting) of fractalkine
3) Confidence 0.09 Published 2010 Journal Expert Opin. Ther. Targets Section Body Doc Link 20055718 Disease Relevance 0.06 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox